Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...

Descripció completa

Dades bibliogràfiques
Autors principals: Na Zheng, Yihao Long, Zixuan Bai, Jianing Li, Hongyu Wang, Dan-Dan Song, Hong-Lin Liu, Jian-Hong Shi, Shuli Zhao
Format: Article
Idioma:English
Publicat: BMC 2024-01-01
Col·lecció:Journal of Translational Medicine
Matèries:
Melatonin
Chimeric antigen receptors
Cytokine release syndrome
Cell- and tissue-based therapy
CD19 antigen
Adoptive immunotherapy
Accés en línia:https://doi.org/10.1186/s12967-023-04779-z

Internet

https://doi.org/10.1186/s12967-023-04779-z

Ítems similars